SWOG clinical trial number
S0313
Evaluation of CHOP Plus Involved Field Radiotherapy followed by Yttrium-90 Ibritumomab Tiuxetan for Stages I, IE and non-bulky Stages II and IIE, CD20 Positive, High-risk Localized, Aggressive Histologies of Non-Hodgkin's Lymphoma, Phase II
Closed
Phase
Accrual
77%
Published
Abbreviated Title
NON-HODGKIN'S: CHOP + IF RT followed by Yttrium-90 Ibritumomab Tiuxetan
Activated
02/01/2004
Closed
12/15/2008
Participants
Limited: Institutions Listed on the Title Page
Research committees
Lymphoma
Treatment
Radiation Therapy
Yttrium-90 ibritumomab tiuxetan
CHOP
Eligibility Criteria Expand/Collapse
Biopsy proven non-Hodgkin's lymphoma (NHL) aggressive histology of one of the following histological subtypes: diffuse large B-cell (formerly Working Formulation Groups F, G, H), high-grade B-cell, Burkitt's or Burkitt-like; anaplastic large cell or mantle cell; Stage I, IE, non-bulky II or IIE; CD-20 positive; at least one of the following: non-bulky Stage II or non-bulky Stage IIE disease, Age >/=60, Zubrod PS=2, serum LDH > IULN; CT scan of chest and CT scan of abdomen/pelvis; bone marrow aspirate and biopsy; no prior RT or chemo for lymphoma; Zubrod PS 0-2; no medical contraindications; documented pre-registraton RT consult; no known HIV.
Publication Information Expand/Collapse
2022
PMid: PMID35833300 | PMC number: PMC9614528
2015
PMid: PMID25395425 | PMC number: PMC4287635
2014
Long term follow up of SWOG S0313: Ibritumomab Tiuxetan consolidation after 3 cycles of CHOP plus radiotherapy for high risk limited stage aggressive B-cell lymphoma (http://www.bloodjournal.org/content/124/21/4414)
2008
Effect of adding ibritumomab tiuxetan (Zevalin) radioimmunotherapy consolidation to three cycles of CHOP plus involved-field radiotherapy for high risk limited stage aggressive diffuse B-cell lymphoma (Southwest Oncology Group Study 0313)
Other Clinical Trials
SWOG Clinical Trial Number
S2207
Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
7%
Open
Phase
SWOG Clinical Trial Number
CTSU/AHOD2131
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase
SWOG Clinical Trial Number
S2114
A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
02/23/2023
Accrual
14%
Open
Phase